交银国际每日晨报-20260318

Core Insights - The report highlights that Legend Biotech is expected to reach breakeven in 2026, with a focus on in vivo CAR-T research moving forward [1][2] - The stock is rated as a "Buy" with a target price of $60.40, indicating a potential upside of 216.2% from the current closing price of $19.10 [1] Financial Performance - In Q4 2025, Legend Biotech reported revenues of $283 million, representing a year-over-year growth of 52% and a quarter-over-quarter growth of 4% [1] - The strong sales of Carvykti contributed significantly, marking the first year of profitability for this product line [1] - The adjusted net profit for Q4 2025 was $2.5 million, indicating a return to profitability for the quarter [1] Market Position and Strategy - Management emphasized the advantages of Carvykti over Tec-Dara in terms of administration convenience and patient survival benefits [2] - Currently, BCMA therapies hold only a 5% market share in the community treatment of 2-4 line multiple myeloma patients in the U.S., indicating significant growth potential [2] - The company, along with its partner Johnson & Johnson, plans to increase annual production capacity to 20,000 doses [2] Future Outlook - The company maintains guidance for a revenue growth of approximately 50% in 2026, with expectations for Carvykti to achieve consecutive quarter-over-quarter growth [1] - Key catalysts for the next 12 months include the CARTITUDE-5 study results expected by the end of 2026 or in the first half of 2027, and a continued shift in R&D focus towards in vivo CAR-T [2]